Solventum Corporation
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 8.17B | 8.13B | 8.20B | 8.25B | 8.32B | 0.9% | |
| Cost of Revenue | (3.25B) | (3.44B) | (3.50B) | (3.66B) | (3.87B) | 5.8% | |
Gross Profit | 4.92B | 4.70B | 4.69B | 4.59B | 4.45B | -3.1% | |
| Operating Expenses | |||||||
| Research & Development | (766.00M) | (767.00M) | (758.00M) | (775.00M) | (739.00M) | -4.6% | |
| Selling, General & Administrative | (2.28B) | (2.23B) | (2.24B) | (2.78B) | (3.08B) | 10.7% | |
| Depreciation & Amortization | (597.00M) | (578.00M) | (561.00M) | (555.00M) | (489.00M) | -11.9% | |
Operating Income (EBIT) | 1.88B | 1.69B | 1.69B | 1.04B | 2.18B | 110.5% | |
| Non-Operating Items | |||||||
| Interest Income | — | — | — | — | — | — | |
| Interest Expense | — | — | — | (367.00M) | (347.00M) | -5.4% | |
| Other Income/Expenses (Net) | 3.00M | -1.00M | -25.00M | -431.00M | -468.00M | 8.6% | |
Income Before Tax | 1.88B | 1.69B | 1.67B | 605.00M | 1.71B | 183.1% | |
| Income Tax Expense | (422.00M) | (349.00M) | (321.00M) | (127.00M) | (157.00M) | 23.6% | |
Net Income | 1.46B | 1.34B | 1.35B | 479.00M | 1.56B | 224.8% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $8 | $8 | $8 | $3 | $9 | 222.7% | |
| Weighted Avg Shares Outstanding | 172.47M | 172.47M | 172.71M | 173.20M | 174.10M | 0.5% | |
| Weighted Avg Shares Outstanding (Diluted) | 172.47M | 172.47M | 172.71M | 173.70M | 175.30M | 0.9% | |
EBITDA | 2.48B | 2.27B | 2.23B | 1.53B | 2.55B | 66.9% |
Explore SOLV
SOLV in the Healthcare
Large Cap